Balyasny Asset Management
TSBX

Balyasny Asset Management’s Turnstone Biologics TSBX Stock Holding History

Balyasny Asset Management’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-49,880
Closed -$27.8K – 3270
2024
Q3 		$27.8K Sell
49,880
-3,802
-7% -$5.84K ﹤0.01% 2658
2024
Q2 		$141K Buy
53,682
+20,936
+64% +$59.8K ﹤0.01% 2379
2024
Q1 		$85.8K Buy
+32,746
New +$93.7K ﹤0.01% 2504

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Balyasny Asset Management's TSBX Position: Q4 2024 in Review

Balyasny Asset Management sold out of Turnstone Biologics (TSBX) in Q4 2024, closing a stake of 49,880 shares — an estimated $27.8K sold.

Balyasny Asset Management first reported a position in TSBX in Q1 2024 and held it in 3 quarters. The position peaked at $141K in Q2 2024. 28 funds tracked by Wall St. Rank hold TSBX as of Q4 2024.

  • Balyasny Asset Management reported no remaining Turnstone Biologics position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 49,880 Turnstone Biologics shares in Q4 2024, an estimated $27.8K.
  • Balyasny Asset Management first reported a position in Turnstone Biologics in Q1 2024 and held it in 3 quarters.
  • Balyasny Asset Management's Turnstone Biologics position peaked at $141K in Q2 2024.
  • 28 funds tracked by Wall St. Rank held Turnstone Biologics as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.